The UAB Research Foundation (The University of Alabama at Birmingham)

Virtual Drug Development, Inc.

Phase One Health, LLC

R Stephen Porter

Lawrence James DeLucas

Wayne J Brouillette

Christie G Brouillette

Sadanandan Velu

Yong-Chul Kim

Liyuan Mou

Jack Fisher

Disclosed are compounds that inhibit the microbial NAD synthetase enzyme. For example, disclosed are compounds of the formula Ar&#x2014;X&#x2014;Ar&#x2014;Y&#x2014;L&#x2014;Z&#x2014;Q, wherein Q is QAror ArQ; Ar, Ar, and Arare independently aryl or heteroaryl, optionally substituted with one or more substituents; X, Y, and Z are independently selected from the group consisting of a covalent bond or groups containing one or more of C, H, N, O, S atoms; L is a linker and Qis an alkylenyl, alkylenyl carbonyloxy alkyl, or alkylenyl carbonylamino alkyl group, optionally having a substituent; a covalent bond; a group containing amidine or guanidine function wherein the amidine or guanidine may be optionally N-substituted with an alkyl; or a zwitterion; or a pharmaceutically acceptable salt thereof. Also disclosed are methods which involve the use of the compounds of the present invention, for example, in treating or preventing a microbial infection in a mammal or plant, killing a prokaryote or decreasing prokaryotic growth, disinfecting a material or environment contaminated by a microbe, increasing food animal production, controlling harm to plants by a pest or insect, and combating agroterrorism. Examples of microbes affected by the compounds of the present invention are bacteria and fungi.

NAD synthetase inhibitors and uses thereof

Growing community of inventors

Brentwood, TN, United States of America

R Stephen Porter